natgillin/translations-raw huggingface dataset:
A rise in haemoglobin of greater than 2 g/dl (1.24 mmol/l) over a four-week period should be avoided. 
Treba izbjegavati porast hemoglobina veći od 2 g/dl (1,24 mmol/l) tijekom 4 tjedna.
Physical, cognitive, or sexual developments in the offspring of mothers receiving methoxy polyethylene glycol-epoetin beta during gestation and lactation were not affected. 
Nije bilo utjecaja na fizički, kognitivni niti reproduktivni razvoj potomaka čije su majke primale metoksi polietilenglikol-epoetin beta tijekom gestacije i dojenja.
MIRCERA stimulates erythropoiesis by interaction with the erythropoietin receptor on progenitor cells in the bone marrow. 
MIRCERA potiče eritropoezu interakcijom s eritropoetinskim receptorima na progenitorskim stanicama u koštanoj srži.
Sodium dihydrogen phosphate monohydrate, sodium sulphate, mannitol (E421), methionine, poloxamer 188 and water for injections. 
Natrijev dihidrogenfosfat hidrat, natrijev sulfat, manitol (E421), metionin, poloksamer 188 i voda za injekcije.
· Never reattach the needle shield after removal. 
• Nikada nemojte vraćati zaštitni pokrov na iglu nakon što ga skinete.
Subcutaneous use is preferable in patients who are not receiving haemodialysis to avoid puncture of peripheral veins. 
U bolesnika koji nisu na hemodijalizi poželjnija je supkutana primjena radi izbjegavanja uboda u periferne vene.
After initiation of therapy, your doctor will seek to maintain your haemoglobin level between 10 and 12 g/dl (7.45 mmol/l). 
Nakon početka terapije, liječnik će Vam razinu hemoglobina nastojati održavati između 10 i 12 g/dl (7,45 mmol/l).
If all the conditions mentioned are excluded and the patient has a sudden drop of haemoglobin associated with reticulocytopenia and anti-erythropoietin antibodies, examination of the bone marrow for the diagnosis of Pure Red Cell Aplasia (PRCA) should be considered. 
Ako se isključe sva navedena stanja, a u bolesnika dođe do iznenadnog pada hemoglobina povezanog s retikulocitopenijom i antieritropoetinskim antitijelima, treba napraviti pretrage koštane srži da bi se utvrdilo postoji li izolirana aplazija crvene krvne loze (engl.
· The expiration date has passed. 
• ako je istekao rok valjanosti
Data from a controlled clinical trial with epoetin alfa or darbepoetin alfa reported an incidence of stroke as common. 
Prema podacima iz kontroliranog kliničkog ispitivanja s epoetinom alfa odnosno darbepoetinom alfa, incidencija moždanoga udara bila je česta.
The absolute bioavailability of methoxy polyethylene glycol-epoetin beta after subcutaneous administration was 54%. 
Apsolutna bioraspoloživost metoksi polietilenglikol-epoetina beta nakon supkutane primjene bila je 54%.
· Do not throw away used syringes or the sharps/ puncture-resistant container in household trash and do not recycle them. 
• Nemojte baciti upotrijebljene štrcaljke ili spremnik za oštre predmete/neprobojni spremnik u kućni otpad i nemojte ih reciklirati.
MIRCERA is available, for all strengths, in pack sizes of 1 and also packsize of 3 for the strengths 30, 50, 75 micrograms/0.3ml. 
MIRCERA je u svim dozama dostupna u pakiranjima od 1 napunjene štrcaljke te u pakiranju od 3 napunjene štrcaljke samo za doze od 30, 50, 75 mikrograma/0,3 ml.
If one dose of MIRCERA is missed, the missed dose is to be administered as soon as possible and administration of MIRCERA is to be restarted at the prescribed dosing frequency. 
Ako se propusti jedna doza lijeka MIRCERA, propuštenu dozu treba primijeniti što je prije moguće, a zatim nastaviti primjenu lijeka MIRCERA u propisanim intervalima.
The safety data base from clinical trials comprised 3,042 CKD patients, including 1,939 patients treated with MIRCERA and 1,103 with another ESA. 
Podaci o sigurnosti prikupljeni tijekom kliničkih ispitivanja dobiveni su od 3042 bolesnika s kroničnom bolesti bubrega, od čega je 1939 bolesnika liječeno lijekom MIRCERA, a 1103 nekim drugim LSE.
Treatment with MIRCERA has to be initiated under the supervision of a physician experienced in the management of patients with renal impairment. 
Liječenje lijekom MIRCERA mora započeti pod nadzorom liječnika s iskustvom u liječenju bolesnika s narušenom funkcijom bubrega.
Platelet counts below 100 x 109/l were observed in 7% of patients treated with MIRCERA and 4% of patients treated with other ESAs during clinical development. 
Broj trombocita niži od 100 x 109/l opažen je u 7% bolesnika liječenih lijekom MIRCERA i 4% bolesnika liječenih drugim LSE.
No dose adjustment is required in patients aged 65 years or older. 
Za bolesnike starije od 65 godina nije potrebna prilagodba doze.
The first MIRCERA dose will be given on the planned injection day of your previous medicine. 
Prva doza lijeka MIRCERA primijenit će se na dan planirane primjene prethodnog lijeka.
Patients treated once every two weeks whose haemoglobin concentration is above 10 g/dl (6.21 mmol/l) may receive MIRCERA administered once-monthly using the dose equal to twice the previous once-every-two-week dose. 
Bolesnici liječeni jedanput svaka dva tjedna čija je koncentracija hemoglobina iznad 10 g/dl (6,21 mmol/l), mogu primiti lijek MIRCERA jedanput mjesečno u dozi dvostruko većoj od one koja je prethodno primjenjivana jedanput svaka dva tjedna.
Further increases of approximately 25% may be made at monthly intervals until the individual target haemoglobin level is obtained. 
Svakih mjesec dana doza se smije povećavati za daljnjih 25% dok se ne postignu ciljne vrijednosti hemoglobina za pojedinog bolesnika.
In responding to hypoxia, the natural hormone erythropoietin interacts with erythroid progenitor cells to increase red cell production. 
Odgovarajući na hipoksiju prirodni hormon eritropoetin djeluje na eritroidne progenitorske stanice kako bi se povećala proizvodnja crvenih krvnih stanica.
These antibodies have been shown to cross-react with all ESAs, and patients suspected or confirmed to have antibodies to erythropoietin should not be switched to MIRCERA (see section 4.8). 
Utvrđeno je da ta antitijela križno reagiraju sa svim lijekovima za stimulaciju eritropoeze pa bolesnici za koje se sumnja ili za koje je potvrđeno da imaju antitijela na eritropoetin ne smiju prelaziti na liječenje lijekom MIRCERA (vidjeti dio 4.8).
Prefilled syringes 30, 50, 75 micrograms are available in pack size of 1 or 3 pre-filled syringe(s). 
Napunjene štrcaljke od 30, 50 i 75 mikrograma dostupne su u veličini pakiranja od 1 ili 3 napunjene štrcaljke.
Pre-filled syringe (type I glass) with laminated plunger stopper (bromobutyl rubber) and tip cap (bromobutyl rubber) and a needle 27G1/2. 
Napunjena štrcaljka (staklo tipa I) s laminiranim čepom klipa (brombutil guma) i zatvaračem vrha (brombutil guma) te jedna igla 27G1/2.
In case PRCA is diagnosed, therapy with MIRCERA must be discontinued and patients should not be switched to another ESA. 
Ako se dijagnosticira PRCA, terapija lijekom MIRCERA mora se prekinuti, a bolesnike se ne smije prebaciti na liječenje nekim drugim LSE.
Your doctor will carry out regular blood tests to monitor how your anaemia is responding to treatment by measuring your haemoglobin level. 
Liječnik će Vas redovito slati na krvne pretrage kako bi uz pomoć izmjerenih vrijednosti razine hemoglobina pratio kako se Vaša anemija odgovara na liječenje.
Remove the needle shield and prepare for injection 
Korak 5. Skinite zaštitni pokrov igle i pripremite se za injekciju
If you are advised to inject MIRCERA under your skin, please administer your dose as described below. 
Ako Vam je zdravstveni radnik savjetovao da lijek MIRCERA injicirate pod kožu, molimo primijenite dozu na način opisan u nastavku.
You may remove your MIRCERA pre-filled syringe from the refrigerator and store it at a room temperature not above 30 °C for a single period of one month. 
MIRCERA napunjenu štrcaljku možete izvaditi iz hladnjaka i čuvati je na sobnoj temperaturi do 30°C u trajanju do mjesec dana.
In a single dose study, after intravenous administration, the pharmacokinetics of methoxy polyethylene glycol-epoetin beta are similar in patients with severe hepatic impairment as compared to healthy subjects (see section 4.2). 
U ispitivanju jednokratne doze, farmakokinetika metoksi polietilenglikol-epoetina beta nakon intravenske primjene bila je slična u bolesnika s teškim oštećenjem funkcije jetre i u zdravih ispitanika (vidjeti dio 4.2).
If you forget to use MIRCERA 
Ako ste zaboravili primiti lijek MIRCERA
Perform the injection 
Korak 6. Primijenite injekciju
To remove air bubbles from the prefilled syringe, hold the syringe with the needle pointing up. 
Da biste uklonili mjehuriće zraka iz napunjene štrcaljke, držite štrcaljku iglom okrenutom prema gore.
Pulmonary embolism* 
rijetko plućna embolija*
Package leaflet: Information for the user 
Uputa o lijeku: Informacije za korisnika MIRCERA
Previous weekly epoetin intravenous or subcutaneous dose (IU/week) 
Prethodna tjedna doza epoetina intravenski ili supkutano (i.j./tjedan)
· Do not remove the needle shield that protects the needle. 
• Nemojte skinuti pokrov za iglu koji štiti iglu.
It did not induce a proliferative response in non-haematological tumor cell lines in vitro. 
Lijek in vitro nije poticao proliferaciju staničnih linija nehematoloških tumora.
One animal study has shown excretion of methoxy polyethylene glycol-epoetin beta in maternal milk. 
Jedno ispitivanje na životinjama pokazalo je da se metoksi polietilenglikol-epoetin beta izlučuje u mlijeko ženki.
In patients with a poor haemoglobin response to epoetins, alternative explanations for the poor response should be considered (see section 4.2 and 5.1). 
U bolesnika sa slabim hemoglobinskim odgovorom na epoetine potrebno je razmotriti druga moguća objašnjenja slabog odgovora (vidjeti dijelove 4.2 i 5.1).
Break the seal of the needle, using a twisting motion, and remove the needle cap as pictured. 
Prelomite spoj igle kružnim pokretom i uklonite zatvarač igle kako je prikazano na slici.
The first injection should start at the next scheduled dose of the previously administered darbepoetin alfa or epoetin. 
Prvu injekciju treba primijeniti u planiranom terminu sljedeće doze darbepoetina alfa ili epoetina.
Patients with hepatic impairment 
Bolesnici s oštećenom funkcijom jetre
You will not receive another ESA and your doctor will treat you for this condition. 
Nećete dobivati drugi lijek za stimulaciju eritropoeze, a liječnik će Vam propisati terapiju za ovo stanje.
Do not use MIRCERA 
Nemojte primati lijek MIRCERA
STORAGE Keep the syringe and the puncture-resistant/ sharps container out of the reach of children. 
Čuvajte štrcaljku i neprobojan spremnik/spremnik za oštre predmete izvan dohvata djece.
Methoxy polyethylene glycol-epoetin beta, the active substance of MIRCERA, is a continuous erythropoietin receptor activator that shows a different activity at the receptor level characterized by a slower association to and faster dissociation from the receptor, a reduced specific activity in vitro with an increased activity in vivo, as well as an increased half-life, in contrast to erythropoietin. 
U usporedbi s eritropoetinom, pokazuje različitu aktivnost na razini receptora koju karakterizira sporija asocijacija i brža disocijacija s receptora, smanjena specifična aktivnost in vitro i povećana aktivnost in vivo te dulji poluvijek.
MIRCERA comes in pre-filled syringes with laminated plunger stopper and tip cap with one needle 27G1/2. 
MIRCERA je dostupna u napunjenim štrcaljkama s laminiranim čepom klipa i zatvaračem vrha te s jednom iglom 27G1/2.
· Never pull on or handle the syringe by its plunger. 
• Nikada nemojte štrcaljku vući za klip niti rukovati njome držeći je za klip.
Before treatment with MIRCERA 
Prije liječenja lijekom MIRCERA
Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin target range of 10 g/dl (6.21 mmol/l) to 12 g/dl (7.45 mmol/l). 
Fluktuaciju hemoglobina treba rješavati korekcijom doze, uzimajući u obzir da je ciljni raspon hemoglobina od 10 g/dl (6,21 mmol/l) do 12 g/dl (7,45 mmol/l).
METHOD AND ROUTE(S) OF ADMINISTRATION For subcutaneous or intravenous use Read the package leaflet before use Do not shake 
NAČIN I PUT(EVI) PRIMJENE LIJEKA Za supkutanu ili intravensku primjenu Prije uporabe pročitajte uputu o lijeku Ne tresti
In a post-authorisation safety study with long treatment exposure of up to 8.4 years, baseline platelet counts below 100 x 109/l was present in 2.1% of patients in the MIRCERA group and 2.4% of patients in other ESAs group. 
U ispitivanju sigurnosti nakon dobivanja odobrenja, u kojem se ispitivala sigurnost lijeka kod dugoročne izloženosti (do 8,4 godine), početni broj trombocita niži od 100 x 109/l bio je prisutan u 2,1% bolesnika u skupini liječenoj lijekom MIRCERA i u 2,4% bolesnika u skupini koja je primala druge lijekove za stimulaciju eritropoeze.
The pharmacokinetics of methoxy polyethylene glycol-epoetin beta were studied in healthy volunteers and in anaemic patients with CKD including patients on dialysis and not on dialysis. 
Farmakokinetika metoksi polietilenglikol-epoetina beta je ispitivana u zdravih dobrovoljnih ispitanika te anemičnih bolesnika s kroničnom bolesti bubrega na dijalizi i onih koji nisu na dijalizi.
Survival and tumour progression have been examined in five large controlled studies involving a total of 2,833 patients, of which four were double-blind placebo-controlled studies and one was an openlabel study. 
Preživljenje i napredovanje tumora ispitivani su u pet velikih kontroliranih studija koje su uključivale ukupno 2833 bolesnika.
The elimination half-life after intravenous administration of methoxy polyethylene glycol-epoetin beta is 134 hours. 
Poluvrijeme eliminacije metoksi polietilenglikol-epoetina beta nakon intravenske primjene iznosi 134 sata.
Following subcutaneous administration to CKD patients on dialysis, the maximum serum concentrations of methoxy polyethylene glycol-epoetin beta were observed 72 hours (median value) after administration. 
Nakon supkutane primjene u bolesnika s kroničnom bolesti bubrega na dijalizi, maksimalne koncentracije metoksi polietilenglikol-epoetina beta u serumu opažene su 72 sata (medijan vrijednosti) nakon primjene.
Caution should be exercised with escalation of MIRCERA doses in patients with chronic renal failure. 
Potreban je oprez prilikom povećanja doza lijeka MIRCERA u bolesnika s kroničnim zatajenjem bubrega.
Keep the pre-filled syringe in the outer carton in order to protect from light 
Napunjenu štrcaljku čuvajte u vanjskom pakiranju radi zaštite od svjetlosti
Prefilled syringes 40, 60, 100, 120, 150, 200, 250 and 360 micrograms are available in pack size of 1 pre-filled syringe. 
Napunjene štrcaljke od 40, 60, 100, 120, 150, 200, 250 i 360 mikrograma dostupne su u veličini pakiranja od 1 napunjene štrcaljke.
• hot flush 
• naleti vrućine
Misuse of MIRCERA by healthy people may lead to an excessive increase in haemoglobin. 
Zlouporaba lijeka MIRCERA u zdravih osoba može dovesti do prekomjernog povećanja razine hemoglobina što može uzrokovati po život opasne kardiovaskularne komplikacije.
MIRCERA should be administered either subcutaneously or intravenously in order to increase haemoglobin to not greater than 12 g/dl (7.45 mmol/l). 
Lijek MIRCERA treba davati supkutano ili intravenski da bi se razina hemoglobina povećala na razinu koja nije viša od 12 g/dl (7,45 mmol/l).
As with other ESAs, cases of thrombosis, including pulmonary embolism, have been reported in the post-marketing setting (see section 4.4). 
Kao i kod ostalih LSE, nakon puštanja lijeka u promet zabilježeni su slučajevi tromboze, uključujući plućnu emboliju (vidjeti dio 4.4).
· Do not inject areas that could be irritated by a belt or waistband. 
• Nemojte injicirati lijek na područja koja bi mogao nadražiti remen ili elastični pojas.
In patients with a poor haemoglobin response to MIRCERA, alternative explanations for the poor response should be considered (see section 4.4 and 5.1). 
U bolesnika sa slabim hemoglobinskim odgovorom na lijek MIRCERA potrebno je razmotriti druga moguća objašnjenja slabog odgovora (vidjeti dijelove 4.4 i 5.1).
Roche Pharma AG Emil-Barrell-Strasse 1 D-79639 Grenzach-Wyhlen Germany 
Roche Pharma AG Emil-Barrell-Strasse 1 D-79639 Grenzach-Wyhlen Njemačka
One pre-filled syringe contains: 30, 40, 50, 60, 75, 100, 120, 150, 200 or 250 micrograms in 0.3 ml and 360 micrograms in 0.6 ml. 
Jedna napunjena štrcaljka sadrži 30, 40, 50, 60, 75, 100, 120, 150, 200 ili 250 mikrograma u 0,3 ml otopine i 360 mikrograma u 0,6 ml otopine.
Each pre-filled syringe contains 0.3 ml or 0.6 ml. 
Jedna napunjena štrcaljka sadrži 0,3 ml ili 0,6 ml otopine.
Pure Red Cell Aplasia caused by anti-erythropoietin antibodies has been reported in association with all ESAs, including MIRCERA. 
Izolirana aplazija crvene krvne loze prouzročena antieritropoetinskim antitijelima zabilježena je uz sve LSE, uključujući lijek MIRCERA.
Hypersensitivity reactions, including cases of anaphylactic reaction and serious skin rashes including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis have been reported in association with epoetin treatement. 
Prijavljivane su reakcije preosjetljivosti, uključujući slučajeve anafilaktičke reakcije i ozbiljne kožne osipe, uključujući Stevens-Johnsonov sindrom i toksičnu epidermalnu nekrolizu, povezani s liječenjem epoetinom.
Fully insert the needle into the skin in a quick, “dart-like” motion. 
Ubodite iglu do kraja u kožu brzim pokretom, poput strelice.
Stop using Mircera if you develop these symptoms and contact your doctor or seek medical attention immediately, see also section 2. 
Prestanite primjenjivati lijek Mircera u slučaju nastanka tih simptoma i odmah se obratite svojem liječniku ili potražite medicinsku pomoć.
Allow the pre-filled syringe to reach room temperature before injecting. 
Prije injiciranja pričekajte da napunjena štrcaljka poprimi sobnu temperaturu.
The solution is clear, colourless to slightly yellowish and free of visible particles. 
Otopina je bistra, bezbojna do blago žućkasta i bez vidljivih čestica.
METHOD AND ROUTE(S) OF ADMINISTRATION For subcutaneous or intravenous use Read the package leaflet before use 
NAČIN I PUT(EVI) PRIMJENE LIJEKA Za supkutanu ili intravensku primjenu Prije uporabe pročitajte uputu o lijeku
Pre-filled syringe 360 micrograms contains 0.6 ml solution. 
Napunjena štrcaljka od 360 mikrograma koja sadrži 0,6 ml otopine.
Follow the recommendations of your healthcare professional about how you should inject MIRCERA. 
Slijedite preporuke koje Vam je za injiciranje lijeka MIRCERA dao zdravstveni radnik.
MIRCERA 30 micrograms/0.3 ml solution for injection in pre-filled syringe MIRCERA 40 micrograms/0.3 ml solution for injection in pre-filled syringe MIRCERA 50 micrograms/0.3 ml solution for injection in pre-filled syringe MIRCERA 60 micrograms/0.3 ml solution for injection in pre-filled syringe MIRCERA 75 micrograms/0.3 ml solution for injection in pre-filled syringe MIRCERA 100 micrograms/0.3 ml solution for injection in pre-filled syringe MIRCERA 120 micrograms/0.3 ml solution for injection in pre-filled syringe MIRCERA 150 micrograms/0.3 ml solution for injection in pre-filled syringe MIRCERA 200 micrograms/0.3 ml solution for injection in pre-filled syringe MIRCERA 250 micrograms/0.3 ml solution for injection in pre-filled syringe MIRCERA 360 micrograms/0.6 ml solution for injection in pre-filled syringe 
MIRCERA 30 mikrograma/0,3 ml otopina za injekciju u napunjenoj štrcaljki MIRCERA 40 mikrograma/0,3 ml otopina za injekciju u napunjenoj štrcaljki MIRCERA 50 mikrograma/0,3 ml otopina za injekciju u napunjenoj štrcaljki MIRCERA 60 mikrograma/0,3 ml otopina za injekciju u napunjenoj štrcaljki MIRCERA 75 mikrograma/0,3 ml otopina za injekciju u napunjenoj štrcaljki MIRCERA 100 mikrograma/0,3 ml otopina za injekciju u napunjenoj štrcaljki MIRCERA 120 mikrograma/0,3 ml otopina za injekciju u napunjenoj štrcaljki MIRCERA 150 mikrograma/0,3 ml otopina za injekciju u napunjenoj štrcaljki MIRCERA 200 mikrograma/0,3 ml otopina za injekciju u napunjenoj štrcaljki MIRCERA 250 mikrograma/0,3 ml otopina za injekciju u napunjenoj štrcaljki MIRCERA 360 mikrograma/0,6 ml otopina za injekciju u napunjenoj štrcaljki
Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening or fatal, have been reported in association with epoetin treatment (see section 4.8). 
Prijavljene su teške kožne nuspojave, uključujući Stevens-Johnsonov sindrom i toksičnu epidermalnu nekrolizu, povezane s liječenjem epoetinom, koje mogu biti opasne po život ili smrtonosne (vidjeti dio 4.8).
During treatment with MIRCERA 
Tijekom liječenja lijekom MIRCERA
No adjustments of the starting dose nor of the dose modification rules are required in patients with hepatic impairment (see section 5.2). 
U bolesnika s oštećenom funkcijom jetre nije potrebno prilagođavati početnu dozu niti mijenjati smjernice za prilagodbu doze (vidjeti dio 5.2).
During the study, platelet counts below 100 x 109/l were observed yearly in 1.5% to 3.0% of patients treated with MIRCERA and 1.6% to 2.5% of patients treated with other ESAs.' 
Tijekom ispitivanja, broj trombocita niži od 100 x 109/l opažen je svake godine u 1,5% - 3,0% bolesnika liječenih lijekom MIRCERA te u 1,6% - 2,5% bolesnika koji su primali druge lijekove za stimulaciju eritropoeze.
• If you are not currently treated with an ESA If you are not on dialysis, the recommended starting dose of MIRCERA is 1.2 micrograms for every kilogram of your body weight to be administered under the skin once every month as a single injection. 
Ako niste na dijalizi preporučena početna doza lijeka MIRCERA iznosi 1,2 mikrograma po kilogramu tjelesne težine, primijenjeno jednom injekcijom pod kožu jedanput mjesečno.
Insert the needle of the pre-filled syringe into the cleaned venous port. 
Uvedite iglu napunjene štrcaljke u očišćeni otvor za injekciju na venskoj liniji.
Attach the needle to the syringe by pushing it firmly onto the syringe. 
Pričvrstite iglu na štrcaljku čvrsto je pritišćući na štrcaljku.
If a dose adjustment is required to maintain the target haemoglobin concentration above 10 g/dl (6.21 mmol/l), the monthly dose may be increased by approximately 25%. 
Ako je za održavanje ciljne koncentracije hemoglobina iznad 10 g/dl (6,21 mmol/l) potrebna prilagodba doze, mjesečna se doza može povećati za otprilike 25%.
Following subcutaneous administration to CKD patients not on dialysis, the maximum serum concentrations of methoxy polyethylene glycol-epoetin beta were observed 95 hours (median value) after administration. 
Nakon supkutane primjene u bolesnika s kroničnom bolesti bubrega koji nisu bili na dijalizi, maksimalne koncentracije metoksi polietilenglikol-epoetina beta u serumu opažene su 95 sati (medijan) nakon primjene.
Prefilled syringes 30, 40, 50, 60, 75, 100, 120, 150, 200 and 250 micrograms contain 0.3 ml solution. 
Napunjene štrcaljke od 30, 40, 50, 60, 75, 100, 120, 150, 200 i 250 mikrograma koje sadrže 0,3 ml otopine.
You may inject MIRCERA into the upper arm, thigh or abdomen, except around the navel (belly button). 
Lijek MIRCERA možete injicirati u nadlakticu, bedro ili trbuh, osim područja oko pupka.